[HTML] sciencedirect.com

[HTML][HTML] Long-term follow-up and exploratory analysis of lenvatinib in patients with metastatic or recurrent thymic carcinoma: Results from the multicenter, phase 2 …

S Niho, J Sato, M Satouchi, S Itoh, Y Okuma… - Lung Cancer, 2024 - Elsevier
Objectives The main objective of this report was to detail the long-term follow-up data from
the REMORA study, which investigated the safety and efficacy of lenvatinib in patients with …
相关文章
[HTML] lungcancerjournal.info

[HTML][HTML] Long-term follow-up and exploratory analysis of lenvatinib in patients with metastatic or recurrent thymic carcinoma: Results from the multicenter, phase 2 …

S Niho, J Sato, M Satouchi, S Itoh, Y Okuma… - Lung …, 2024 - lungcancerjournal.info
Objectives The main objective of this report was to detail the long-term follow-up data from
the REMORA study, which investigated the safety and efficacy of lenvatinib in patients with …

Long-term follow-up and exploratory analysis of lenvatinib in patients with metastatic or recurrent thymic carcinoma: Results from the multicenter, phase 2 REMORA …

S Niho, J Sato, M Satouchi, S Itoh, Y Okuma… - Lung Cancer …, 2024 - europepmc.org
Objectives The main objective of this report was to detail the long-term follow-up data from
the REMORA study, which investigated the safety and efficacy of lenvatinib in patients with …

Long-term follow-up and exploratory analysis of lenvatinib in patients with metastatic or recurrent thymic carcinoma: Results from the multicenter, phase 2 REMORA …

S Niho, J Sato, M Satouchi, S Itoh… - Lung cancer … - pubmed.ncbi.nlm.nih.gov
Objectives The main objective of this report was to detail the long-term follow-up data from
the REMORA study, which investigated the safety and efficacy of lenvatinib in patients with …